全文获取类型
| 收费全文 | 25033篇 |
| 免费 | 1445篇 |
| 国内免费 | 213篇 |
专业分类
| 耳鼻咽喉 | 269篇 |
| 儿科学 | 498篇 |
| 妇产科学 | 494篇 |
| 基础医学 | 2733篇 |
| 口腔科学 | 795篇 |
| 临床医学 | 2027篇 |
| 内科学 | 6418篇 |
| 皮肤病学 | 287篇 |
| 神经病学 | 3051篇 |
| 特种医学 | 885篇 |
| 外科学 | 4275篇 |
| 综合类 | 60篇 |
| 一般理论 | 3篇 |
| 预防医学 | 987篇 |
| 眼科学 | 471篇 |
| 药学 | 1328篇 |
| 中国医学 | 30篇 |
| 肿瘤学 | 2080篇 |
出版年
| 2024年 | 15篇 |
| 2023年 | 273篇 |
| 2022年 | 618篇 |
| 2021年 | 1056篇 |
| 2020年 | 624篇 |
| 2019年 | 841篇 |
| 2018年 | 880篇 |
| 2017年 | 684篇 |
| 2016年 | 772篇 |
| 2015年 | 834篇 |
| 2014年 | 1125篇 |
| 2013年 | 1457篇 |
| 2012年 | 2133篇 |
| 2011年 | 2160篇 |
| 2010年 | 1121篇 |
| 2009年 | 1098篇 |
| 2008年 | 1606篇 |
| 2007年 | 1577篇 |
| 2006年 | 1447篇 |
| 2005年 | 1340篇 |
| 2004年 | 1282篇 |
| 2003年 | 1037篇 |
| 2002年 | 937篇 |
| 2001年 | 142篇 |
| 2000年 | 97篇 |
| 1999年 | 136篇 |
| 1998年 | 170篇 |
| 1997年 | 150篇 |
| 1996年 | 130篇 |
| 1995年 | 100篇 |
| 1994年 | 103篇 |
| 1993年 | 77篇 |
| 1992年 | 68篇 |
| 1991年 | 64篇 |
| 1990年 | 57篇 |
| 1989年 | 66篇 |
| 1988年 | 36篇 |
| 1987年 | 29篇 |
| 1986年 | 42篇 |
| 1985年 | 26篇 |
| 1984年 | 45篇 |
| 1983年 | 36篇 |
| 1982年 | 37篇 |
| 1981年 | 31篇 |
| 1980年 | 26篇 |
| 1979年 | 19篇 |
| 1978年 | 11篇 |
| 1976年 | 8篇 |
| 1974年 | 12篇 |
| 1973年 | 8篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
A case of Rubinstein‐Taybi syndrome associated with growth hormone deficiency in childhood 
下载免费PDF全文
下载免费PDF全文 2.
3.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献4.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献5.
Alessia Scarselli Silvia Di Cesare Claudia Capponi Simona Cascioli Maria L. Romiti Gigliola Di Matteo Alessandra Simonetti Paolo Palma Andrea Finocchi Barbarella Lucarelli Rita M. Pinto Ippolita Rana Giuseppe Palumbo Maurizio Caniglia Paolo Rossi Rita Carsetti Caterina Cancrini Alessandro Aiuti 《Journal of clinical immunology》2015,35(4):373-383
6.
7.
8.
9.
10.